Eli Lilly and Company stock slips to EUR 1,227.50, down 0.58% premarket
Published on 11/20/2026 at 07:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLilly weighs volume against pricing
- Barclays raised its Eli Lilly price target to USD 1,550 from USD 1,400 while keeping an Overweight rating on November 16.
- Third-quarter revenue rose 39 percent to USD 24.4 billion as volume increased 53 percent, while realized prices declined 15 percent.
- Lilly's Innovation Day is scheduled for December 7, with investors watching for growth plans beyond obesity medicines.
Eli Lilly and Company stock traded at EUR 1,227.50 on Lang & Schwarz at 07:56 CET on Friday, November 20, 2026, 0.58 percent below the Xetra close of Thursday, November 19, 2026, at EUR 1,234.60.
Barclays raised its price target for Eli Lilly to USD 1,550 from USD 1,400 on November 16 and maintained an Overweight rating. Yahoo Finance reported that the move followed Lilly's third-quarter performance and stronger volume trends.
Lilly's third-quarter revenue rose 39 percent to USD 24.4 billion, according to the report. Volume increased 53 percent, more than offsetting a 15 percent decline in realized prices. The company also lifted its 2026 revenue guidance by USD 5.5 billion at the midpoint to a range of USD 91 billion to USD 92 billion.
The pricing trend remains a key issue for investors because Lilly's growth depends on volume gains continuing to exceed lower realized prices. The company is due to hold its Innovation Day on December 7, while first 2027 guidance is expected in January.
Broader sentiment can be followed through the S&P 500 market.
